Jun Park

Professional Career 

  • 2020-Present, a member of Global Pharma Key Opinion Leader (GPKOL) for CMC/cGMP, Korea Health Industry Development Institute 
  • 2020-Present: ILIAS Biologics, Chief Technology Officer, Daejeon, Korea 

Development of innovative exosome-based therapies that use exosomes as carriers for intracellular protein delivery. 

  • 2017-2019: Helixmith, SVP/Head of CMC, Seoul, Korea 

Development of gene therapies for neuromuscular diseases using plasmid DNA. 

  • 2006-2017: US FDA/CDER/Office of Biotechnology Products, Maryland, USA 

Worked as a CMC reviewer for biotech and biosimilar product reviews  

Participated in cGMP manufacturing facility inspections. 

  • 1999-2006: US DOD, Edgewood Chemical Biological Center, Maryland, USA 

Research on biologic agents and small-scale production of proteins, monoclonal antibodies, and enzymes. 

  • 1989-1999: Alpha-Beta Technology, Massachusetts, USA 

Development of carbohydrate-based therapies for immunomodulator or wound healing, etc. 



  • Worcester Polytechnic Institute, Ph.D., Biochemical Engineering, Massachusetts, USA 
  • KAIST, MS, Chemical Engineering, Seoul, Korea 
  • Yonsei University, BS, Chemical Engineering, Seoul, Korea